SCHEMBL1672816

SCHEMBL1672816

O=C1C[C@H](CC(F)(F)F)CN1

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21550321 1.00 SYK (0.33) SYK
SCHEMBL6950382 1.00 SYK (0.33) SYK
SCHEMBL1673183 0.84 SYK (0.32) SYK
SCHEMBL12690059 0.84 SYK (0.32) SYK
SCHEMBL2947840 0.84 SYK (0.34) SYK
SCHEMBL19486191 0.81 SYK (0.34) SYK
SCHEMBL24365329 0.80 PDE3B (0.35)
SCHEMBL1671939 0.80 SYK (0.32) SYK
SCHEMBL1671842 0.80 SYK (0.32) SYK
SCHEMBL30497404 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3724198-B1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Biopharma SRL (BE) 2022-02-16 EP disclosed
US-11155566-B2 2-OXO-1-pyrrolidinyl imidazothiadiazole derivatives UCB Biopharma SRL 2021-10-26 US disclosed
US-20200399288-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2020-12-24 US disclosed
WO-2019115292-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2019-06-20 WO disclosed
EP-2491045-B1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2015-12-23 EP disclosed
US-8822508-B2 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives UCB PHARMA, S.A. (BE) 2014-09-02 US disclosed
US-20120245208-A1 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives UCB PHARMA, S.A. (BE) 2012-09-27 US disclosed
EP-2491045-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB Pharma S.A. (BE) 2012-08-29 EP disclosed
WO-2011047860-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES UCB PHARMA, S.A. (BE) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399288-A1 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES CYP3A4, CYP3A43, CYP3A7 SYK 2834/4885
US-11155566-B2 2-OXO-1-pyrrolidinyl imidazothiadiazole derivatives CYP3A4, CYP3A43, CYP3A7 SYK 2834/4885
US-20120245208-A1 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives CYP3A4, CYP3A43, CYP3A7 SYK 2758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.